Welcome to our dedicated page for Nukkleus Warrants news (Ticker: NUKKW), a resource for investors and traders seeking the latest updates and insights on Nukkleus Warrants stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nukkleus Warrants's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nukkleus Warrants's position in the market.
Nukkleus (NASDAQ: NUKK) announced a 1-for-8 reverse stock split effective October 24, 2024. The split aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement by November 4, 2024. Post-split, NUKK's outstanding shares will reduce from 16.9 million to approximately 2.1 million. The company's authorized shares were increased from 40 million to 150 million at the October 11 annual meeting. No fractional shares will be issued, and stockholders will receive rounded-up shares. The split won't alter stockholders' ownership percentages or voting power. Continental Stock Transfer & Trust Company is managing the exchange process for stockholders.
FAQ
What is the current stock price of Nukkleus Warrants (NUKKW)?
What is the market cap of Nukkleus Warrants (NUKKW)?
